Compare Lululemon Athletica Inc (LULU) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Novo Nordisk A/S — how do they compare? Lululemon Athletica Inc trades at $94.5 (market cap $10.27B), while Novo Nordisk A/S trades at $38.64 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 16.1× Lululemon Athletica Inc's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lululemon Athletica Inc for 105 Days and Novo Nordisk A/S for 116 Days on average.
| LULU | NVO | |
|---|---|---|
Market Cap | $10.27B | $165.31B |
Volume | 4,392,324 | 11,432,838 |
Sector | Consumer Cyclical | Health |
52-Week High | $215.88 | $63.98 |
52-Week Low | $91.88 | $35.29 |
Typical Hold Time | 105 Days | 116 Days |
Enterprise Value | $11.02B | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon (LULU) stock trades at $92.68, down 54% year-to-date and near its 52-week low. The technical outlook is bearish, while fundamentals show strong profitability with a 56.11% gross margin and a low P/E of 7.63. Recent earnings beats are overshadowed by a revenue decline and multiple securities fraud investigations announced in late September 2026.
The stock presents a value opportunity based on depressed valuation multiples, but significant risks exist from legal scrutiny, competitive pressures, and weakening growth. Analyst consensus is a 'Hold' with a $97.67 price target, indicating cautious optimism amid high uncertainty.
Novo Nordisk (NVO) trades at $38.18, down 0.21% with a bearish technical signal. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (35.35% net margin, 59.82% ROE). Recent news highlights pipeline developments including Wegovy pill data and a $4 billion licensing deal, though the FDA extended review of its hemophilia drug. Cash flow remains positive at $10.81B for 2025, supporting dividend payments.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 17% upside to the $44.67 consensus target. However, competitive pressure from Eli Lilly's obesity drug pipeline and regulatory delays pose near-term risks. Analyst sentiment is bullish (59% buy ratings), but investors should monitor Q3 2026 earnings against the 0.753 EPS expectation for confirmation of growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
